No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ACAD240517P15000
- 0.28
- -0.37-56.92%
15min DelayClose May 9 15:49 ET
0.28High0.17Low
0.25Open0.65Pre Close56 Volume353 Open Interest15.00Strike Price1.00KTurnover43.54%IV-3.22%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.28Time Value100Contract SizeAmericanOptions Type-0.3949Delta0.3995Gamma54.32Leverage Ratio-0.0239Theta-0.0012Rho-21.45Eff Leverage0.0085Vega
Intraday
- 5D
- 1D
News
Express News | ACADIA Pharmaceuticals Inc : Guggenheim Cuts Target Price to $26 From $30
Neutral Outlook on ACADIA Pharmaceuticals Amidst Revenue Miss and Revised Penetration Forecasts
Buy Rating for ACADIA Pharmaceuticals Based on Promising Drug Prospects and Financial Stability
Express News | ACADIA Pharmaceuticals Inc : Oppenheimer Cuts Target Price to $17 From $19
Daybue Guidance Looks Achievable for Acadia, Neuren -- Market Talk
0011 GMT - Acadia Pharmaceuticals' target of $370 million-$420 million net sales of its Daybue treatment for Retts Syndrome looks achievable to Jefferies, despite a small miss in 1Q. In a research not
Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million
Neuren Pharmaceuticals (ASX:NEU) partner Acadia Pharmaceuticals (NASDAQ:ACAD) posted Q1 net sales of its DAYBUE treatment in the US of $75.9 million, below its guidance of $76 million to $82 million,
Comments
Analysts have high confidence in ACADIA Pharmaceuticals, predicting an average annual growth rate of 42%. The company's lack of debt reduces concerns around repayments and makes it a less risky investment.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) On The Verge Of Breaking Even 1
Several companies were in the spotlight due to various developments:
Oracle ( $Oracle(ORCL.US$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $ACADIA Pharmaceuticals(ACAD.US$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts(MTN.US$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$Asana(ASAN.US$ Asana rep...
Oracle ( $Oracle(ORCL.US$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $ACADIA Pharmaceuticals(ACAD.US$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts(MTN.US$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$Asana(ASAN.US$ Asana rep...
2
$ACADIA Pharmaceuticals(ACAD.US$ And where will the bottom be? Could it be a opportunity? Time will tell? Hehehe![]()
$ACADIA Pharmaceuticals(ACAD.US$ Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effe...
1
6
Read more